Tradestie Institutional Equity Comparison Engine

MRNA vs ADPT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MRNA Overall Edge

MRNA Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Moderna, Inc. Common Stock (MRNA) driven by superior Valuation, Momentum & Technical while ADPT counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus ADPT at N/M Forward P/E and -16.2% operating margin (-10.7% YoY). In options structure, MRNA sits in CONSOLIDATION (64th %ile IV; Dealer Gamma Walls on Pro) against ADPT sits in BREAKOUT (36th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MRNA
MRNA 23.0x vs ADPT N/M Fwd P/E
Growth & Margin Winner ADPT
Op Margin -80.8% vs -16.2% ยท YoY +29.2% vs -10.7%
Momentum & Technical Winner MRNA
1Y +731.3% vs +102.5% ยท 52W Pos 71% vs 82%
Options & Structure Winner ADPT
CONSOLIDATION (64th %ile IV) vs BREAKOUT (36th %ile IV)
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$205.91
-4.35% 1D
Market Cap $90.4B
1M Return -9.25%
1Y Return +731.29%
Forward P/E 23.0x
Unified AI Score
46.6 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 67.0 Mom 46.0
ADPT NASDAQ
Adaptive Biotechnologies Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$28.56
+2.48% 1D
Market Cap $4.7B
1M Return +19.25%
1Y Return +102.55%
Forward P/E N/M
Unified AI Score
43.2 / 100 HOLD
Tech 15.0 Fund 42.0 Flow 68.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MRNA +731.29% ADPT +102.55% Spread: +628.74 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period MRNA Revenue ADPT Revenue MRNA Op. Margin ADPT Op. Margin Margin Edge
FY2018 $140M $60M -306.0% -89.4% ADPT
FY2019 $60M $90M -906.8% -92.1% ADPT
FY2020 $800M $100M -95.0% -155.3% MRNA
FY2021 $18.5B $150M 72.0% -135.4% MRNA
FY2022 $19.3B $190M 48.9% -108.0% MRNA
FY2023 $6.85B $170M -61.9% -133.3% MRNA
FY2024 $3.24B $180M -121.9% -90.8% ADPT
FY2025 $1.94B $280M -158.1% -20.6% ADPT

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MRNA (6) vs ADPT (4)
Institutional Metric MRNA ADPT Criterion Row Winner
Market Capitalization Scale $90.4B $4.7B Larger Scale MRNA
Trailing P/E Ratio Valuation 23.0x N/M Lower Multiple MRNA
Forward P/E Ratio Valuation 23.0x N/M Lower Multiple MRNA
Revenue Growth (YoY) Growth +29.2% -10.7% Higher Growth MRNA
Operating Margin (TTM) Profitability -80.8% -16.2% Higher Margin ADPT
Net Profit Margin Profitability -110.5% -23.7% Higher Margin ADPT
Return on Equity (ROE) Capital Efficiency -34.5% -36.4% Higher ROE MRNA
52-Week Range Position Momentum 71% ($22โ€“$281) 82% ($12โ€“$32) Stronger Trend ADPT
Beta / 30D Volatility Risk Regime 2.37ฮฒ ยท 100% Vol 1.73ฮฒ ยท 59% Vol Lower Realized Risk ADPT
Unified Institutional Score Composite Signal 46.6 / 100 (HOLD) 43.2 / 100 (HOLD) Higher Composite MRNA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MRNA vs ADPT Buy Guide
MRNA CONSOLIDATION
19d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 64th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ADPT BREAKOUT
70d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 36th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ADPT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MRNA nor ADPT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.